Examining the efficacy of toceranib phosphate (Palladia®) as a primary and/or adjuvant agent in the treatment of feline oral squamous cell carcinoma

Study details:

Especies: cats

Tumor type: Oral Squamous Cell Carcinoma

Purpose of study: The objective of this study is to investigate the efficacy of toceranib phosphate (Palladia®) alone or as a radiation-sensitizing agent in the treatment of feline oral squamous cell carcinoma (SCC). Cats will receive Palladia® alone or in combination with palliative radiation therapy. Palladia® will be administered orally on a Monday/Wednesday/Friday schedule for up to one year. Radiation treatments will be delivered twice weekly for three weeks. Owners will elect which treatment the cat will receive: Palladia® alone or Palladia® and radiotherapy. Cats must have a confirmed diagnosis of oral SCC to be eligible for participation in this study.

Once accepted into the study, cats will have a physical examination and repeat laboratory blood work (CBC) performed weekly for the first 3 weeks, at week 5, and then at four-week intervals (week 9, 13, etc.) for up to one year. Palladia® will be provided at no charge to the client. Fees related to tumor staging, radiotherapy (if used), recheck visits, scheduled blood work and treatment of any side effects or unexpected complications are the financial responsibility of the owner. For more information, click here